SPRINGFIELD – On February 11, the U.S. Food and Drug Administration issued an emergency use authorization for a new monoclonal antibody, bebtelovimab, for the
Monoclonal Antibody therapy has been proven to be effective in reducing disease severity and chances of death in high-risk individuals infected with the Delta v
The study found that 75 per cent of patients who got the monoclonal therapy became RT-PCR negative by the seventh day and 78 per cent of them got relieved of their clinical symptoms like fever, cough, etc. in the same duration.
Uniindia: Hyderabad Nov 2 (UNI) AIG (Asian Institute of Gastroenterology) Hospitals along with the Asian Healthcare Foundation, Centre for Cellular & Molecular Biology(CCMB) Hyderabad and Institute of Life Sciences, in their study successfully proved that the Monoclonal antibody Therapy reduces severe disease and death in high-risk individuals infected with the Delta Variant of SARS CoV 2 by 100 per cent.